Learn how to order either FLEXBUMIN or BUMINATE [Albumin (Human)],
5% and 25% Solutions today.
More >
FLEXBUMIN 25% [Albumin (Human)], 25% Solution Versus Human Albumin in Glass Containers
FLEXBUMIN avoids the risk of glass bottle breakage, which
in turn reduces costly clean-up and potential injuries. This chart compares
flexible containers to glass and summarizes the major attributes and
advantages of using a flexible delivery/storage system relating to container
convenience, safety and cost effectiveness.
| Attributes of FLEXBUMIN vs Albumin in a Glass Container | ||
Container Attribute |
FLEXBUMIN |
Glass-container Albumin |
Breakable |
Reduced Risk of Breakage |
Breakable |
Administration Set |
Standard IV sets |
Vented set required |
Storage Space1 |
Shipper Carton (7 x 15 x 20.5 cm) 60% Less – (24) 50 mL or 55% Less – (12) 100 mL |
(24) 50 mL Box (15.5 x 21 x 18.5 cm) (12) 100 mL Box (12.2 x 17.5 x 22.3 cm) |
Weight1 |
(40% less than glass) 50 mL = 66 g/bag 100 mL = 120 g/bag |
50 mL = 113 g 100 mL = 196 g |
Ease of Disposal |
Collapsible container requires less space |
Rigid container requires more space |
Risk of Contamination2-4 |
Closed system |
Open system |
Latex1 |
All components latex-free |
Some stoppers contain latex |
Coring of Stopper |
Reduced risk (no stopper) |
Risk |
PVC or DEHA1 |
Does not contain |
Not Applicable |
FLEXBUMIN 25% [Albumin (Human)]
FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. FLEXBUMIN 25% is indicated for hypovolemia, hypoalbuminemia due to general causes, burns, adult respiratory distress syndrome (ARDS), and nephrosis, and for use during or prior to cardiopulmonary bypass surgery, and hemolytic disease of the newborn (HDN).
Important Risk Information for FLEXBUMIN 25%
FLEXBUMIN 25% is contraindicated in patients with cardiac failure, in patients with severe anemia and in patients with a history of allergic reactions to human albumin.
Do not use if turbid. Do not begin administration more than 4 hours after the container has been entered.
Do not use Sterile Water for Injection as a diluent. There exists a risk of potentially fatal hemolysis and acute renal failure from the inappropriate use of Sterile Water for Injection as a diluent for FLEXBUMIN 25%. Acceptable diluents include 0.9% Sodium Chloride or 5% Dextrose in Water.
FLEXBUMIN 25% is made from pooled human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt–Jakob disease (CJD) agent.
FLEXBUMIN 25% must be administered intravenously at a rate not to exceed 1ml/min to patients with normal blood volume, due to the risk of developing circulatory overload and pulmonary edema.
When 25% albumin is infused, a rise in blood pressure necessitates careful observation to detect and treat severed blood vessels that may not have bled at a lower blood pressure.
Adverse reactions to FLEXBUMIN 25% are extremely rare, although nausea, fever, chills or urticaria may occasionally occur.
CAUTION: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is complete.
Please see Preparation for Administration for FLEXBUMIN 25% in the Prescribing Information.
Please review the FLEXBUMIN 25% [Albumin (Human)] Prescribing Information for full prescribing details.
BUMINATE 5% [Albumin (Human)], USP, 5% Solution
BUMINATE 5% is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. BUMINATE 5% is indicated in hypovolemia, hypoalbuminemia, burns, and cardiopulmonary bypass surgery.
Please see Important Risk Information for BUMINATE 5% and Full Prescribing Information.
BUMINATE 25% [Albumin (Human)], USP, 25% Solution
BUMINATE 25% is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. BUMINATE 25% is indicated in hypovolemia, hypoalbuminemia, burns, adult respiratory distress syndrome (ARDS), nephrosis, cardiopulmonary bypass surgery, and hemolytic disease of the newborn (HDN).
Please see Important Risk Information for BUMINATE 25% and Full Prescribing Information.
- Data on file. Baxter Healthcare Corporation.
- Rosenthal VD, Maki DG. Prospective study of the impact of open and closed infusion systems on rates of central venous catheter-associated bacteremia. American Journal of Infection Control. 2004; 32(3):135-141.
- Franzetti F et al. Impact on rates and time to first central vascular-associated bloodstream infection when switching from open to closed intravenous infusion containers in a hospital setting. Epidemiology and Infection. 2009; 137(7):1041-1048.
- Rangel-Frausto MS et al. Should we use closed or open infusion containers for prevention of bloodstream infections? Annals of Clinical Microbiology and Antimicrobials. 2010; 9:6.
